Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients.
about
Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid populationFluticasone propionate: a potent inhaled corticosteroid for the treatment of asthma.Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management.Relationship between asthma drug therapy patterns and healthcare utilization.The limited incorporation of economic analyses in clinical practice guidelines.Assessing symptoms and peak expiratory flow rate as predictors of asthma exacerbations.Effect of practitioner education on adherence to asthma treatment guidelines.The virtual asthma guideline e-learning program: learning effectiveness and user satisfaction.Using case management to increase antiinflammatory medication use among a managed care population with asthma.Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population.Anti-inflammatory medication adherence, healthcare utilization and expenditures among Medicaid and children's health insurance program enrollees with asthma.Asthma patients' knowledge, perception, and adherence to the asthma guidelines.The control of asthma in Italy. A multicentre descriptive study on young adults with doctor diagnosed current asthma.
P2860
Q30986163-E79C59B9-D97C-4088-BA00-FC1FBA44EDC7Q33774071-042C59DC-56AC-4D43-8820-072F5E963AB1Q34181951-771CA4FF-0B92-4C0F-B21F-C1F26978E3A2Q34523871-35D9C1F4-2EBE-4790-8870-59E7C5B27A5DQ34579601-6AE39A1A-E612-4DDB-B5DF-82C2DECA6D8DQ34585520-7202A536-467D-469D-B3D4-A28F929AEE35Q34731657-751CAFB3-7336-4CB8-B396-FF0676E1577BQ35169425-D2278089-F296-4142-866B-B7B54630C593Q38401020-851A80D4-32E0-493F-A744-E06E98DC24E8Q39409694-8DCE89E1-5631-4BFD-8ABB-191A82B11DE0Q42168327-2ECC0646-3CE9-4BD0-8D11-2172F6BE345CQ46053198-EBF435D1-DF37-4F63-B954-4C6B00EE7BD7Q47697920-B54A357E-C98B-4A62-B521-E78D921E7BF5Q48017323-3F80B8D3-AF6D-4573-AAC9-B14704AE0450
P2860
Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Outcomes and cost benefits ass ...... ulation of asthmatic patients.
@en
Outcomes and cost benefits ass ...... ulation of asthmatic patients.
@nl
type
label
Outcomes and cost benefits ass ...... ulation of asthmatic patients.
@en
Outcomes and cost benefits ass ...... ulation of asthmatic patients.
@nl
prefLabel
Outcomes and cost benefits ass ...... ulation of asthmatic patients.
@en
Outcomes and cost benefits ass ...... ulation of asthmatic patients.
@nl
P2093
P1476
Outcomes and cost benefits ass ...... ulation of asthmatic patients.
@en
P2093
Anderson A
Balkrishnan R
Norwood GJ
P304
P356
10.1016/S0149-2918(98)80066-0
P577
1998-05-01T00:00:00Z